Research ArticleArticle

Validation of the UCLA Scleroderma Clinical Trial Gastrointestinal Tract Instrument Version 2.0 for Systemic Sclerosis

MURRAY BARON, MARIE HUDSON, RUSSELL STEELE, ERNEST LO and the Canadian Scleroderma Research Group
The Journal of Rheumatology September 2011, 38 (9) 1925-1930; DOI: https://doi.org/10.3899/jrheum.110060

REFERENCES

  1. 1.↵
    1. Sjogren RW
    . Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994;37:1265–82.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Lock G,
    2. Holstege A,
    3. Lang B,
    4. Scholmerich J
    . Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol 1997;92:763–71.
    OpenUrlPubMed
  3. 3.↵
    1. Hudson M,
    2. Thombs B,
    3. Steele R,
    4. Watterson R,
    5. Taillefer S,
    6. Baron M,
    7. et al.
    Clinical correlates of quality of life in systemic sclerosis measured with the World Health Organization Disability Assessment Schedule II. Arthritis Rheum 2008;59:279–84.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Hudson M,
    2. Steele R,
    3. Lu Y,
    4. Thombs BD,
    5. Panopalis P,
    6. Baron M
    . Clinical correlates of self-reported physical health status in systemic sclerosis. J Rheumatol 2009;36:1226–9.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Schieir O,
    2. Thombs BD,
    3. Hudson M,
    4. Boivin JF,
    5. Steele R,
    6. Bernatsky S,
    7. et al.
    Prevalence, severity, and clinical correlates of pain in patients with systemic sclerosis. Arthritis Care Res 2010;62:409–17.
    OpenUrlCrossRef
  6. 6.↵
    1. Thombs BD,
    2. Hudson M,
    3. Taillefer SS,
    4. Baron M;
    5. Canadian Scleroderma Research Group
    . Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis. Arthritis Rheum 2008;59:504–9.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Thombs BD,
    2. Hudson M,
    3. Bassel M,
    4. Taillefer SS,
    5. Baron M
    . Sociodemographic, disease, and symptom correlates of fatigue in systemic sclerosis: evidence from a sample of 659 Canadian Scleroderma Research Group Registry patients. Arthritis Rheum 2009;61:966–73.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. El-Baalbaki G,
    2. Razykov I,
    3. Hudson M,
    4. Bassel M,
    5. Baron M,
    6. Thombs BD
    . The association of pruritus with quality of life and disability in systemic sclerosis. Arthritis Care Res 2010;62:1489–95.
    OpenUrlCrossRef
  9. 9.↵
    1. Baron M,
    2. Hudson M,
    3. Steele R
    . Malnutrition is common in systemic sclerosis: results from the Canadian Scleroderma Research Group database. J Rheumatol 2009;36:2737–43.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Steen VD,
    2. Medsger TA Jr.
    . Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437–44.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Khanna D,
    2. Hays RD,
    3. Maranian P,
    4. Seibold JR,
    5. Impens A,
    6. Mayes MD,
    7. et al.
    Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 2009;61:1257–63.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Khanna D,
    2. Hays RD,
    3. Park GS,
    4. Braun-Moscovici Y,
    5. Mayes MD,
    6. McNearney TA,
    7. et al.
    Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. Arthritis Rheum 2007;57:1280–6.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Khanna D,
    2. Furst DE,
    3. Clements PJ,
    4. Park GS,
    5. Hays RD,
    6. Yoon J,
    7. et al.
    Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005;32:832–40.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Khanna D,
    2. Clements PJ,
    3. Furst DE,
    4. Chon Y,
    5. Elashoff R,
    6. Roth MD,
    7. et al.
    Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005;52:592–600.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Khanna D,
    2. Yan X,
    3. Tashkin DP,
    4. Furst DE,
    5. Elashoff R,
    6. Roth MD,
    7. et al.
    Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the Scleroderma Lung Study. Arthritis Rheum 2007;56:1676–84.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Tashkin DP,
    2. Elashoff R,
    3. Clements PJ,
    4. Roth MD,
    5. Furst DE,
    6. Silver RM,
    7. et al.
    Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007;176:1026–34.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Avouac J,
    2. Sordet C,
    3. Depinay C,
    4. Ardizonne M,
    5. Vacher-Lavenu MC,
    6. Sibilia J,
    7. et al.
    Systemic sclerosis-associated Sjogren’s syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum 2006;54:2243–9.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Steen VD,
    2. Medsger TA Jr.
    . The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984–91.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Joliffe IT,
    2. Morgan BJ
    . Principal component analysis and exploratory factor analysis. Stat Methods Med Res 1992;1:69–95.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Shaw M,
    2. Talley NJ,
    3. Adlis S,
    4. Beebe T,
    5. Tomshine P,
    6. Healey M
    . Development of a digestive health status instrument: tests of scaling assumptions, structure and reliability in a primary care population. Aliment Pharmacol Ther 1998;12:1067–78.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Clements P,
    2. Lachenbruch P,
    3. Siebold J,
    4. White B,
    5. Weiner S,
    6. Martin R,
    7. et al.
    Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281–5.
    OpenUrlPubMed
  22. 22.↵
    1. R Development Core Team
    . R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2008.
  23. 23.↵
    1. Pedhauzer E,
    2. Schmelkin L
    . Measurement, design and analysis. An integrated approach. Mahwah, NJ: Lawrence Erlbaum Associates; 1991:37–9.
  24. 24.↵
    1. Constandriopoulos A,
    2. Champagne F,
    3. Potvin L,
    4. Denis J,
    5. Boyle P
    . [Savoir preparer une recherche.] Montreal: Universite de Montreal; 1989:53–60.
  25. 25.↵
    1. Bodukam V,
    2. Hays RD,
    3. Maranian P,
    4. Furst DE,
    5. Seibold JR,
    6. Impens A,
    7. et al.
    Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. Rheumatology 2011;50:330–4.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section